Shares of Bio-Techne Corp. TECH shed 6.03% to $54.86 Thursday, on what proved to be an all-around dismal trading session for ...

Shareholders of Bio-Techne would probably like to forget the past six months even happened. The stock has dropped 26.9% and ...

In a report released on April 1, Conor McNamara from RBC Capital maintained a Hold rating on Bio-Techne (TECH – Research Report), with a price ...

Bio-Techne (TECH) announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics, or ACD, ...

Bio-Techne Corporation TECH recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa (“EMEA”) region. The facility's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bio-Techne reported second-quarter fiscal 2025 adjusted earnings per share of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The bottom line improved from the year-ago figure of ...

In the preceding three months, 6 analysts have released ratings for Bio-Techne (NASDAQ:TECH), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates ...

Shares of Bio-Techne Corp. TECH shed 2.18% to $57.35 Tuesday, on what proved to be an all-around mixed trading session for ...

Bio-Techne Corporation TECH recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa (“EMEA”) region. The facility ...